Evidence map›Paper›PMID 33609168›Full record

ArticleWorld journal of urology2021

The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies.

Cécile Manceau, Gaëlle Fromont-Hankard, Jean-Baptiste Beauval, Marine Lesourd, Christophe Almeras, Anne-Sophie Bajeot, Jean-Romain Gautier, Michel Soulié, Guillaume Loison, Ambroise Salin and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cécile ManceauDepartment of Urology, CHU-IUCT Oncopole, 1 Av du Professeur Jean Poulhès, 31400, Toulouse, France. Cecile.manceau2@gmail.com.ORCID http://orcid.org/0000-0003-1597-4767
Gaëlle Fromont-HankardDepartment of Pathological Anatomy and Cytology, CHRU Tours, Inserm UMR 1069, Tours, France.
Jean-Baptiste BeauvalDepartment of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
Marine LesourdDepartment of Urology, CHU-IUCT Oncopole, 1 Av du Professeur Jean Poulhès, 31400, Toulouse, France.
Christophe AlmerasDepartment of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
Anne-Sophie BajeotDepartment of Urology, CHU-IUCT Oncopole, 1 Av du Professeur Jean Poulhès, 31400, Toulouse, France.
Jean-Romain GautierDepartment of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
Michel SouliéDepartment of Urology, CHU-IUCT Oncopole, 1 Av du Professeur Jean Poulhès, 31400, Toulouse, France.
Guillaume LoisonDepartment of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
Ambroise SalinDepartment of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
Christophe TollonDepartment of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
Bernard MalavaudDepartment of Urology, CHU-IUCT Oncopole, 1 Av du Professeur Jean Poulhès, 31400, Toulouse, France.
Mathieu RoumiguiéDepartment of Urology, CHU-IUCT Oncopole, 1 Av du Professeur Jean Poulhès, 31400, Toulouse, France.
Guillaume PloussardDepartment of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the proportion and risk factors for downgrading and reclassification to favorable disease in patients having high-grade (HG) prostate cancer (PCa) pattern on magnetic resonance imaging (MRI)-targeted-biopsy (TB).

methodsFrom a radical prostatectomy (RP) cohort, we included patients with pre-biopsy positive MRI and HG [defined by Grade Group (GG) ≥ 3] PCa on MRI-TB. All patients also underwent concomitant systematic biopsy (SB). The main endpoints were the rates of downgrading to GG2, overall downgrading, favorable disease (pT2 and GG2) on RP specimens, and biochemical recurrence-free-survival (RFS). We studied the correlations between HG on concomitant SB, final pathological outcomes and biochemical RFS curves.

resultsOverall downgrading, downgrading to GG2 disease and favorable disease were noted in 36.2%, 24.1%, and 15.4% respectively. HG on concomitant SB was correlated with pT3-4 disease (p < 0.001), pN1 disease (p < 0.001), positive surgical margins (p = 0.043), PSA recurrence (p = 0.003). In multivariable analysis, the presence of GG4-5 on TB (p = 0.013; OR 0.263) and the presence of HG on concomitant SB (p = 0.010; OR 0.269) were negatively and independently correlated with the risk of downgrading to GG2. The presence of HG on concomitant SB independently predicted RFS with a hazard ratio of 2.173 (p = 0.049; 95% CI 1.005-4.697).

conclusionsOur data shows that a limited HG restricted to TB can often be associated with a favorable grade in almost a quarter of the cases and downgraded in almost half of the cases. Detailed SB features, mainly the presence of HG on concomitant SB, was associated with a more accurate pathology and oncologic outcomes prediction, pleading for the maintenance of SB in MRI-positive patients.

Indexed as

Image-Guided BiopsyMagnetic Resonance ImagingBiopsyHumansMaleNeoplasm GradingPrognosisProstateProstatic NeoplasmsRetrospective StudiesDowngradingMRIProstate cancerRadical prostatectomySystematic biopsyTargeted biopsy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.